In contrast, met formin inhibited cell proliferation in both wild-type and AMPKa (1/2) null mefs as well as in AMPK silenced ovarian cancer cells.
These results provide evidence on the role of metformin as an anti-proliferative therapeutic that can act through both AMPK-dependent as well as AMPK-independent pathways.